Payment overview · 2025
General Payments
$1,499.98
44 reported records · 16 companies
Healthcare provider profile · identity verified
Yu Yao, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN GABRIEL, CA · NPI 1356307821
Verified facts
What the public records show
CMS Open Payments records show Yu Yao, M.D. received $1,499.98 in general payments during 2025 across 44 reported records.
GlaxoSmithKline, LLC. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Kerendia, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 320 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $331.95 | 22.1% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $316.99 | 21.1% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $269.23 | 17.9% | 7 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $138.50 | 9.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.27 | 8.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.85 | 4.0% | 3 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $47.15 | 3.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $29.86 | 2.0% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $28.71 | 1.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.45 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.90 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.10 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.79 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.83 | 1.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $19.78 | 1.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.62 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,499.98 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $299.36 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $269.23 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $195.16 | 5 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $138.50 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.27 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $59.85 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $53.50 | 4 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $47.15 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.59 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $28.71 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 218 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 320 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 140 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
218 | 54 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
140 | 47 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
117 | 63 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
320 | 70 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 3088 | 912 |
| Amlodipine Besylate | Amlodipine Besylate | 2822 | 723 |
| Losartan Potassium | Losartan Potassium | 1605 | 411 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 1368 | 528 |
| Metformin Hcl | Metformin Hcl | 895 | 231 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 759 | 345 |
| Pravastatin Sodium | Pravastatin Sodium | 751 | 219 |
| Pantoprazole Sodium | Pantoprazole Sodium | 739 | 226 |
| Omeprazole | Omeprazole | 736 | 297 |
| Gabapentin | Gabapentin | 701 | 259 |
| Zolpidem Tartrate | Zolpidem Tartrate | 619 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 589 | 138 |
| Metoprolol Succinate | Metoprolol Succinate | 587 | 154 |
| Azithromycin | Azithromycin | 583 | 438 |
| Lorazepam | Lorazepam | 577 | 105 |
| Nifedipine Er | Nifedipine | 576 | 119 |
| Prednisone | Prednisone | 492 | 335 |
| Tamsulosin Hcl | Tamsulosin Hcl | 435 | 132 |
| Alendronate Sodium | Alendronate Sodium | 432 | 132 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 432 | 97 |
| Atenolol | Atenolol | 431 | 104 |
| Vascepa | Icosapent Ethyl | 411 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 404 | 133 |
| Clopidogrel | Clopidogrel Bisulfate | 376 | 95 |
| Januvia | Sitagliptin Phosphate | 376 | 65 |
| Hydralazine Hcl | Hydralazine Hcl | 366 | 123 |
| Raloxifene Hcl | Raloxifene Hcl | 363 | 92 |
| Meloxicam | Meloxicam | 361 | 169 |
| Donepezil Hcl | Donepezil Hcl | 356 | 92 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 331 | 113 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 324 | 83 |
| Glimepiride | Glimepiride | 323 | 85 |
| Jardiance | Empagliflozin | 320 | 70 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 308 | 94 |
| Simvastatin | Simvastatin | 307 | 75 |
| Icosapent Ethyl | Icosapent Ethyl | 301 | 87 |
| Azelastine Hcl | Azelastine Hcl | 293 | 119 |
| Cephalexin | Cephalexin | 291 | 217 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 262 | 218 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 248 | 96 |
| Carvedilol | Carvedilol | 241 | 66 |
| Creon | Lipase/Protease/Amylase | 218 | 54 |
| Montelukast Sodium | Montelukast Sodium | 214 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 205 | 94 |
| Famotidine | Famotidine | 205 | 82 |
| Cyclosporine | Cyclosporine | 196 | 69 |
| Finasteride | Finasteride | 195 | 54 |
| Glipizide | Glipizide | 187 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 183 | 74 |
| Eliquis | Apixaban | 182 | 37 |
| Allopurinol | Allopurinol | 178 | 42 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 153 | 131 |
| Furosemide | Furosemide | 148 | 39 |
| Meclizine Hcl | Meclizine Hcl | 147 | 91 |
| Mirtazapine | Mirtazapine | 145 | 46 |
| Procto-Med Hc | Hydrocortisone | 142 | 57 |
| Hydrocortisone | Hydrocortisone | 140 | 70 |
| Linzess | Linaclotide | 140 | 47 |
| Amoxicillin | Amoxicillin | 139 | 103 |
| Fluocinonide | Fluocinonide | 138 | 62 |
| Sildenafil Citrate | Sildenafil Citrate | 138 | 33 |
| Memantine Hcl | Memantine Hcl | 137 | 31 |
| Dexlansoprazole Dr | Dexlansoprazole | 136 | 24 |
| Mometasone Furoate | Mometasone Furoate | 134 | 66 |
| Temazepam | Temazepam | 134 | 26 |
| Valsartan | Valsartan | 134 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 49 |
| Sertraline Hcl | Sertraline Hcl | 127 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 126 | 24 |
| Paxlovid | Nirmatrelvir/Ritonavir | 124 | 119 |
| Telmisartan | Telmisartan | 121 | 31 |
| Propranolol Hcl | Propranolol Hcl | 120 | 34 |
| Ezetimibe | Ezetimibe | 118 | 40 |
| Lactulose | Lactulose | 118 | 53 |
| Prolia | Denosumab | 117 | 63 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 115 | 45 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 115 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 107 | 27 |
| Restasis | Cyclosporine | 105 | 40 |
| Bepotastine Besilate | Bepotastine Besilate | 101 | 28 |
| Mupirocin | Mupirocin | 101 | 71 |
| Celecoxib | Celecoxib | 99 | 31 |
| Tradjenta | Linagliptin | 99 | 14 |
| Lisinopril | Lisinopril | 98 | 23 |
| Clonidine Hcl | Clonidine Hcl | 95 | 34 |
| Colchicine | Colchicine | 95 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 26 |
| Lansoprazole | Lansoprazole | 91 | 36 |
| Potassium Chloride | Potassium Chloride | 91 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 89 | 27 |
| Lidocaine | Lidocaine | 85 | 17 |
| Trazodone Hcl | Trazodone Hcl | 81 | 19 |
| Erythromycin | Erythromycin Base | 80 | 41 |
| Benazepril Hcl | Benazepril Hcl | 78 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 77 | 44 |
| Pregabalin | Pregabalin | 75 | 11 |
| Felodipine Er | Felodipine | 74 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 71 | 38 |
| Acyclovir | Acyclovir | 71 | 50 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 30 |
| Alprazolam | Alprazolam | 68 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 57 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 17 |
| Nitroglycerin | Nitroglycerin | 66 | 47 |
| Ibuprofen | Ibuprofen | 65 | 44 |
| Ofloxacin | Ofloxacin | 65 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 19 |
| Triazolam | Triazolam | 59 | suppressed |
| Ketoconazole | Ketoconazole | 55 | 29 |
| Ranolazine Er | Ranolazine | 54 | 11 |
| Ammonium Lactate | Ammonium Lactate | 53 | 23 |
| Ciclopirox | Ciclopirox | 52 | 23 |
| Dutasteride | Dutasteride | 52 | 18 |
| Megestrol Acetate | Megestrol Acetate | 52 | 25 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 49 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 12 |
| Folic Acid | Folic Acid | 48 | 12 |
| Irbesartan | Irbesartan | 48 | 12 |
| Baclofen | Baclofen | 47 | 21 |
| Candesartan Cilexetil | Candesartan Cilexetil | 47 | 13 |
| Sucralfate | Sucralfate | 47 | 12 |
| Farxiga | Dapagliflozin Propanediol | 46 | 12 |
| Metformin Hcl Er | Metformin Hcl | 45 | 13 |
| Ciclopirox | Ciclopirox Olamine | 44 | 27 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 40 | 12 |
| Myrbetriq | Mirabegron | 40 | 12 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 40 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Latanoprost | Latanoprost | 39 | 13 |
| Levofloxacin | Levofloxacin | 38 | 34 |
| Methimazole | Methimazole | 38 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 18 |
| Labetalol Hcl | Labetalol Hcl | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 29 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 32 | 17 |
| Constulose | Lactulose | 32 | 16 |
| Saxagliptin Hcl | Saxagliptin Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | 11 |
| Vemlidy | Tenofovir Alafenamide | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | 12 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 29 | 21 |
| Promethazine-Dm | Promethazine/Dextromethorphan | 29 | 25 |
| Pilocarpine Hcl | Pilocarpine Hcl | 28 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 24 |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Nateglinide | Nateglinide | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Entecavir | Entecavir | 22 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 22 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ursodiol | Ursodiol | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lumigan | Bimatoprost | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 12 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Acarbose | Acarbose | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 15 |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Benicar | Olmesartan Medoxomil | 15 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Mitigare | Colchicine | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Silodosin | Silodosin | 15 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 14 | 11 |
| Crestor | Rosuvastatin Calcium | 14 | suppressed |
| Diovan | Valsartan | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Fanapt | Iloperidone | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Lovaza | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Adefovir Dipivoxil | Adefovir Dipivoxil | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,499.98 · 44 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, CREON, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Kerendia, LINZESS, LOREEV XR, Ozempic, PANCREAZE, PYRUKYND, SHINGRIX, TRELEGY ELLIPTA, Tymlos | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error